Search Results

You are looking at 71 - 80 of 486 items for :

  • "locally advanced" x
  • Refine by Access: All x
Clear All
Full access

” were added. PANC-F 6 of 8 • Heading was modified: Second-line Subsequent Therapy for Locally Advanced/Metastatic Disease and Therapy for Recurrent Disease.

Full access

Mokenge P. Malafa

. Pancreatic cancer presents as a continuum, from resectable local disease, to locally advanced unresectable disease because of the involvement of surrounding critical vascular structures. Since the 1990s, a subset of patients between resectable and locally

Full access

Masaki Shiota

prognosis. 3 Meanwhile, in the randomized SPCG-4 trial in Europe, therapy with radical prostatectomy (RP) showed a superior outcome to observation. 4 Furthermore, the addition of radiotherapy to PADT for locally advanced disease was shown to improve

Full access

James L. Mohler

responded to ADT, according to the 2013 PATCH trial, which involved patients with locally advanced disease. 1 In that study, investigators found that patients responded equally as well to the estrogen patch as to a luteinizing hormone-releasing hormone

Full access

Matthew D. Galsky, Harry W. Herr, and Dean F. Bajorin

: Plenary debate of randomized phase III trial of neoadjuvant MVAC plus cystectomy versus cystectomy alone in patients with locally advanced bladder cancer . J Clin Oncol 2001 ; 19 : 17S – 20S . 10 Splinter TA Scher HI Denis L . The prognostic

Full access

Chemoradiation in HPV-Negative and High-Risk HPV-Positive Locally Advanced Stage III/IVa/IVb Squamous Cell Carcinoma of the Head and Neck Institutional Principal Investigators: Shanthi Marur, MD, and Jill Gilbert, MD Condition: Squamous cell carcinoma of

Full access

-723-3657 • dklebus@stanford.edu ClinicalTrials.gov Identifier: NCT00946673 Phase I Study of the HDAC Inhibitor Vorinostat With Chemotherapy and Radiation Therapy for the Treatment of Locally Advanced Non–Small Cell Lung Cancer Principal Investigators

Full access

Thomas W. Flaig

. with locally advanced or metastatic urothelial carcinoma who are cisplatin-ineligible. 1 , 2 Analysis of clinical trial data can identify 3 broad populations of patients: (1) those who show response initially and continue to show response (responders

Full access

Al B. Benson III, Alan P. Venook, Tanios Bekaii-Saab, Emily Chan, Yi-Jen Chen, Harry S. Cooper, Paul F. Engstrom, Peter C. Enzinger, Moon J. Fenton, Charles S. Fuchs, Jean L. Grem, Axel Grothey, Howard S. Hochster, Steven Hunt, Ahmed Kamel, Natalie Kirilcuk, Lucille A. Leong, Edward Lin, Wells A. Messersmith, Mary F. Mulcahy, James D. Murphy, Steven Nurkin, Eric Rohren, David P. Ryan, Leonard Saltz, Sunil Sharma, David Shibata, John M. Skibber, Constantinos T. Sofocleous, Elena M. Stoffel, Eden Stotsky-Himelfarb, Christopher G. Willett, Kristina M. Gregory, and Deborah Freedman-Cass

reported on their experience using initial FOLFOX followed by chemoRT and resection in patients with locally advanced rectal cancer. 12 Of the approximately 300 patients, 61 received initial FOLFOX, 4 of whom declined chemoRT after an excellent response

Full access

Ludmila Katherine Martin and Tanios Bekaii-Saab

with locally advanced rectal cancer (T3-4 or N0-1) were randomized to receive either neoadjuvant CRT with capecitabine alone followed by adjuvant capecitabine, or neoadjuvant CRT with capecitabine and oxaliplatin followed by adjuvant capecitabine and